Effect of active anticancer therapy on serologic response to SARS‐CoV‐2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma Article Swipe
Kyo Togashi
,
Shingo Hatakeyama
,
Tohru Yoneyama
,
Tomoko Hamaya
,
Takuma Narita
,
Naoki Fujita
,
Hiromichi Iwamura
,
Teppei Okamoto
,
Hayato Yamamoto
,
Takahiro Yoneyama
,
Yasuhiro Hashimoto
,
Chikara Οhyama
·
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1111/iju.14882
YOU?
·
· 2022
· Open Access
·
· DOI: https://doi.org/10.1111/iju.14882
Objectives To evaluate the serologic response to the BNT162b2 messenger ribonucleic acid vaccine in patients with urothelial carcinoma and renal cell carcinoma. Methods Between June 2021 and November 2021, we retrospectively evaluated blood samples from 60 healthy controls (control group), 57 patients with urothelial carcinoma, and 28 patients with renal cell carcinoma who had received two doses of the BNT162b2 vaccine at Hirosaki University Hospital. We determined the immunoglobulin G antibody titers against the severe acute respiratory syndrome coronavirus 2 spike receptor‐binding domain. Seropositivity was defined as ≥15 U/mL. We investigate factors associated with antibody titers and seropositivity in the patients with urothelial carcinoma and renal cell carcinoma. Results Antibody titers in the control, urothelial carcinoma, and renal cell carcinoma groups were 813, 431, and 500 U/mL, respectively. Seropositivity was 100%, 90%, and 96% in the control, urothelial carcinoma, and renal cell carcinoma groups, respectively. Of the 85 patients, 37 of 57 (65%) and 21 of 28 (75%) were actively undergoing anticancer treatment for urothelial carcinoma and renal cell carcinoma, respectively. Anti‐severe acute respiratory syndrome coronavirus 2 spike immunoglobulin G antibody titers and seropositivity was not significantly different between the patients with urothelial carcinoma and renal cell carcinoma. Anti‐severe acute respiratory syndrome coronavirus 2 spike immunoglobulin G antibody titers were not significantly associated with active anticancer therapy or steroid treatment for immune‐related adverse events. Univariable logistic regression analysis revealed that older age and metastatic disease were significantly and negatively associated with seropositivity. Conclusions Patients with urothelial carcinoma or renal cell carcinoma exhibited an adequate antibody response to the BNT162b2 vaccine. Active anticancer therapy was not significantly associated with seropositivity following vaccination with severe acute respiratory syndrome coronavirus 2 BNT162b2 in patients with urothelial carcinoma and renal cell carcinoma.
Related Topics
Concepts
Medicine
Renal cell carcinoma
Carcinoma
Metastatic Urothelial Carcinoma
Titer
Antibody titer
Antibody
Serology
Nasopharyngeal carcinoma
Internal medicine
Oncology
Gastroenterology
Cancer
Immunology
Bladder cancer
Urothelial carcinoma
Radiation therapy
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.1111/iju.14882
- OA Status
- green
- Cited By
- 5
- References
- 33
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4220814698
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4220814698Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.1111/iju.14882Digital Object Identifier
- Title
-
Effect of active anticancer therapy on serologic response to SARS‐CoV‐2 BNT162b2 vaccine in patients with urothelial and renal cell carcinomaWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2022Year of publication
- Publication date
-
2022-03-31Full publication date if available
- Authors
-
Kyo Togashi, Shingo Hatakeyama, Tohru Yoneyama, Tomoko Hamaya, Takuma Narita, Naoki Fujita, Hiromichi Iwamura, Teppei Okamoto, Hayato Yamamoto, Takahiro Yoneyama, Yasuhiro Hashimoto, Chikara ΟhyamaList of authors in order
- Landing page
-
https://doi.org/10.1111/iju.14882Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
greenOpen access status per OpenAlex
- OA URL
-
https://www.ncbi.nlm.nih.gov/pmc/articles/9111834Direct OA link when available
- Concepts
-
Medicine, Renal cell carcinoma, Carcinoma, Metastatic Urothelial Carcinoma, Titer, Antibody titer, Antibody, Serology, Nasopharyngeal carcinoma, Internal medicine, Oncology, Gastroenterology, Cancer, Immunology, Bladder cancer, Urothelial carcinoma, Radiation therapyTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
5Total citation count in OpenAlex
- Citations by year (recent)
-
2023: 2, 2022: 3Per-year citation counts (last 5 years)
- References (count)
-
33Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4220814698 |
|---|---|
| doi | https://doi.org/10.1111/iju.14882 |
| ids.doi | https://doi.org/10.1111/iju.14882 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/35362143 |
| ids.openalex | https://openalex.org/W4220814698 |
| fwci | 0.74482348 |
| mesh[0].qualifier_ui | |
| mesh[0].descriptor_ui | D000914 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | |
| mesh[0].descriptor_name | Antibodies, Viral |
| mesh[1].qualifier_ui | |
| mesh[1].descriptor_ui | D000090982 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | |
| mesh[1].descriptor_name | BNT162 Vaccine |
| mesh[2].qualifier_ui | Q000517 |
| mesh[2].descriptor_ui | D000086382 |
| mesh[2].is_major_topic | True |
| mesh[2].qualifier_name | prevention & control |
| mesh[2].descriptor_name | COVID-19 |
| mesh[3].qualifier_ui | |
| mesh[3].descriptor_ui | D000086663 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | |
| mesh[3].descriptor_name | COVID-19 Vaccines |
| mesh[4].qualifier_ui | Q000188 |
| mesh[4].descriptor_ui | D002292 |
| mesh[4].is_major_topic | True |
| mesh[4].qualifier_name | drug therapy |
| mesh[4].descriptor_name | Carcinoma, Renal Cell |
| mesh[5].qualifier_ui | Q000188 |
| mesh[5].descriptor_ui | D002295 |
| mesh[5].is_major_topic | True |
| mesh[5].qualifier_name | drug therapy |
| mesh[5].descriptor_name | Carcinoma, Transitional Cell |
| mesh[6].qualifier_ui | |
| mesh[6].descriptor_ui | D006801 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | |
| mesh[6].descriptor_name | Humans |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D007074 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Immunoglobulin G |
| mesh[8].qualifier_ui | Q000188 |
| mesh[8].descriptor_ui | D007680 |
| mesh[8].is_major_topic | True |
| mesh[8].qualifier_name | drug therapy |
| mesh[8].descriptor_name | Kidney Neoplasms |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D012189 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Retrospective Studies |
| mesh[10].qualifier_ui | |
| mesh[10].descriptor_ui | D000086402 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | |
| mesh[10].descriptor_name | SARS-CoV-2 |
| mesh[11].qualifier_ui | Q000188 |
| mesh[11].descriptor_ui | D001749 |
| mesh[11].is_major_topic | True |
| mesh[11].qualifier_name | drug therapy |
| mesh[11].descriptor_name | Urinary Bladder Neoplasms |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D000914 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Antibodies, Viral |
| mesh[13].qualifier_ui | |
| mesh[13].descriptor_ui | D000090982 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | |
| mesh[13].descriptor_name | BNT162 Vaccine |
| mesh[14].qualifier_ui | Q000517 |
| mesh[14].descriptor_ui | D000086382 |
| mesh[14].is_major_topic | True |
| mesh[14].qualifier_name | prevention & control |
| mesh[14].descriptor_name | COVID-19 |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D000086663 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | COVID-19 Vaccines |
| mesh[16].qualifier_ui | Q000188 |
| mesh[16].descriptor_ui | D002292 |
| mesh[16].is_major_topic | True |
| mesh[16].qualifier_name | drug therapy |
| mesh[16].descriptor_name | Carcinoma, Renal Cell |
| mesh[17].qualifier_ui | Q000188 |
| mesh[17].descriptor_ui | D002295 |
| mesh[17].is_major_topic | True |
| mesh[17].qualifier_name | drug therapy |
| mesh[17].descriptor_name | Carcinoma, Transitional Cell |
| mesh[18].qualifier_ui | |
| mesh[18].descriptor_ui | D006801 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | |
| mesh[18].descriptor_name | Humans |
| mesh[19].qualifier_ui | |
| mesh[19].descriptor_ui | D007074 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | |
| mesh[19].descriptor_name | Immunoglobulin G |
| mesh[20].qualifier_ui | Q000188 |
| mesh[20].descriptor_ui | D007680 |
| mesh[20].is_major_topic | True |
| mesh[20].qualifier_name | drug therapy |
| mesh[20].descriptor_name | Kidney Neoplasms |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D012189 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Retrospective Studies |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D000086402 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | SARS-CoV-2 |
| mesh[23].qualifier_ui | Q000188 |
| mesh[23].descriptor_ui | D001749 |
| mesh[23].is_major_topic | True |
| mesh[23].qualifier_name | drug therapy |
| mesh[23].descriptor_name | Urinary Bladder Neoplasms |
| type | article |
| title | Effect of active anticancer therapy on serologic response to SARS‐CoV‐2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma |
| awards[0].id | https://openalex.org/G1888608916 |
| awards[0].funder_id | https://openalex.org/F4320334764 |
| awards[0].display_name | |
| awards[0].funder_award_id | 21K09339 |
| awards[0].funder_display_name | Japan Society for the Promotion of Science |
| awards[1].id | https://openalex.org/G5795922988 |
| awards[1].funder_id | https://openalex.org/F4320334764 |
| awards[1].display_name | |
| awards[1].funder_award_id | 19H05556 |
| awards[1].funder_display_name | Japan Society for the Promotion of Science |
| awards[2].id | https://openalex.org/G8362266089 |
| awards[2].funder_id | https://openalex.org/F4320334764 |
| awards[2].display_name | |
| awards[2].funder_award_id | 20K09517 |
| awards[2].funder_display_name | Japan Society for the Promotion of Science |
| biblio.issue | 7 |
| biblio.volume | 29 |
| biblio.last_page | 739 |
| biblio.first_page | 733 |
| topics[0].id | https://openalex.org/T11296 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9980999827384949 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | COVID-19 and healthcare impacts |
| topics[1].id | https://openalex.org/T10449 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9945999979972839 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2740 |
| topics[1].subfield.display_name | Pulmonary and Respiratory Medicine |
| topics[1].display_name | Renal cell carcinoma treatment |
| topics[2].id | https://openalex.org/T11267 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9767000079154968 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2746 |
| topics[2].subfield.display_name | Surgery |
| topics[2].display_name | Abdominal Trauma and Injuries |
| funders[0].id | https://openalex.org/F4320334764 |
| funders[0].ror | https://ror.org/00hhkn466 |
| funders[0].display_name | Japan Society for the Promotion of Science |
| is_xpac | False |
| apc_list.value | 3400 |
| apc_list.currency | USD |
| apc_list.value_usd | 3400 |
| apc_paid | |
| concepts[0].id | https://openalex.org/C71924100 |
| concepts[0].level | 0 |
| concepts[0].score | 0.8966377377510071 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[0].display_name | Medicine |
| concepts[1].id | https://openalex.org/C2777472916 |
| concepts[1].level | 2 |
| concepts[1].score | 0.8066869974136353 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q1164529 |
| concepts[1].display_name | Renal cell carcinoma |
| concepts[2].id | https://openalex.org/C2777546739 |
| concepts[2].level | 2 |
| concepts[2].score | 0.5945153832435608 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q33525 |
| concepts[2].display_name | Carcinoma |
| concepts[3].id | https://openalex.org/C2911057145 |
| concepts[3].level | 5 |
| concepts[3].score | 0.5124710202217102 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q2501186 |
| concepts[3].display_name | Metastatic Urothelial Carcinoma |
| concepts[4].id | https://openalex.org/C32611913 |
| concepts[4].level | 3 |
| concepts[4].score | 0.5111775994300842 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q2166189 |
| concepts[4].display_name | Titer |
| concepts[5].id | https://openalex.org/C22889606 |
| concepts[5].level | 4 |
| concepts[5].score | 0.49713876843452454 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q2166189 |
| concepts[5].display_name | Antibody titer |
| concepts[6].id | https://openalex.org/C159654299 |
| concepts[6].level | 2 |
| concepts[6].score | 0.49233806133270264 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q79460 |
| concepts[6].display_name | Antibody |
| concepts[7].id | https://openalex.org/C45189115 |
| concepts[7].level | 3 |
| concepts[7].score | 0.45662200450897217 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q502159 |
| concepts[7].display_name | Serology |
| concepts[8].id | https://openalex.org/C2778997737 |
| concepts[8].level | 3 |
| concepts[8].score | 0.4475732445716858 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q1693598 |
| concepts[8].display_name | Nasopharyngeal carcinoma |
| concepts[9].id | https://openalex.org/C126322002 |
| concepts[9].level | 1 |
| concepts[9].score | 0.43809840083122253 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[9].display_name | Internal medicine |
| concepts[10].id | https://openalex.org/C143998085 |
| concepts[10].level | 1 |
| concepts[10].score | 0.4079554080963135 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[10].display_name | Oncology |
| concepts[11].id | https://openalex.org/C90924648 |
| concepts[11].level | 1 |
| concepts[11].score | 0.38271015882492065 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q120569 |
| concepts[11].display_name | Gastroenterology |
| concepts[12].id | https://openalex.org/C121608353 |
| concepts[12].level | 2 |
| concepts[12].score | 0.35715800523757935 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[12].display_name | Cancer |
| concepts[13].id | https://openalex.org/C203014093 |
| concepts[13].level | 1 |
| concepts[13].score | 0.35608360171318054 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[13].display_name | Immunology |
| concepts[14].id | https://openalex.org/C2780352672 |
| concepts[14].level | 3 |
| concepts[14].score | 0.21724960207939148 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q504775 |
| concepts[14].display_name | Bladder cancer |
| concepts[15].id | https://openalex.org/C3019882237 |
| concepts[15].level | 4 |
| concepts[15].score | 0.2100955843925476 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q2501186 |
| concepts[15].display_name | Urothelial carcinoma |
| concepts[16].id | https://openalex.org/C509974204 |
| concepts[16].level | 2 |
| concepts[16].score | 0.06380417943000793 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q180507 |
| concepts[16].display_name | Radiation therapy |
| keywords[0].id | https://openalex.org/keywords/medicine |
| keywords[0].score | 0.8966377377510071 |
| keywords[0].display_name | Medicine |
| keywords[1].id | https://openalex.org/keywords/renal-cell-carcinoma |
| keywords[1].score | 0.8066869974136353 |
| keywords[1].display_name | Renal cell carcinoma |
| keywords[2].id | https://openalex.org/keywords/carcinoma |
| keywords[2].score | 0.5945153832435608 |
| keywords[2].display_name | Carcinoma |
| keywords[3].id | https://openalex.org/keywords/metastatic-urothelial-carcinoma |
| keywords[3].score | 0.5124710202217102 |
| keywords[3].display_name | Metastatic Urothelial Carcinoma |
| keywords[4].id | https://openalex.org/keywords/titer |
| keywords[4].score | 0.5111775994300842 |
| keywords[4].display_name | Titer |
| keywords[5].id | https://openalex.org/keywords/antibody-titer |
| keywords[5].score | 0.49713876843452454 |
| keywords[5].display_name | Antibody titer |
| keywords[6].id | https://openalex.org/keywords/antibody |
| keywords[6].score | 0.49233806133270264 |
| keywords[6].display_name | Antibody |
| keywords[7].id | https://openalex.org/keywords/serology |
| keywords[7].score | 0.45662200450897217 |
| keywords[7].display_name | Serology |
| keywords[8].id | https://openalex.org/keywords/nasopharyngeal-carcinoma |
| keywords[8].score | 0.4475732445716858 |
| keywords[8].display_name | Nasopharyngeal carcinoma |
| keywords[9].id | https://openalex.org/keywords/internal-medicine |
| keywords[9].score | 0.43809840083122253 |
| keywords[9].display_name | Internal medicine |
| keywords[10].id | https://openalex.org/keywords/oncology |
| keywords[10].score | 0.4079554080963135 |
| keywords[10].display_name | Oncology |
| keywords[11].id | https://openalex.org/keywords/gastroenterology |
| keywords[11].score | 0.38271015882492065 |
| keywords[11].display_name | Gastroenterology |
| keywords[12].id | https://openalex.org/keywords/cancer |
| keywords[12].score | 0.35715800523757935 |
| keywords[12].display_name | Cancer |
| keywords[13].id | https://openalex.org/keywords/immunology |
| keywords[13].score | 0.35608360171318054 |
| keywords[13].display_name | Immunology |
| keywords[14].id | https://openalex.org/keywords/bladder-cancer |
| keywords[14].score | 0.21724960207939148 |
| keywords[14].display_name | Bladder cancer |
| keywords[15].id | https://openalex.org/keywords/urothelial-carcinoma |
| keywords[15].score | 0.2100955843925476 |
| keywords[15].display_name | Urothelial carcinoma |
| keywords[16].id | https://openalex.org/keywords/radiation-therapy |
| keywords[16].score | 0.06380417943000793 |
| keywords[16].display_name | Radiation therapy |
| language | en |
| locations[0].id | doi:10.1111/iju.14882 |
| locations[0].is_oa | False |
| locations[0].source.id | https://openalex.org/S134892809 |
| locations[0].source.issn | 0919-8172, 1442-2042 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0919-8172 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | International Journal of Urology |
| locations[0].source.host_organization | https://openalex.org/P4310320595 |
| locations[0].source.host_organization_name | Wiley |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320595 |
| locations[0].source.host_organization_lineage_names | Wiley |
| locations[0].license | |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | International Journal of Urology |
| locations[0].landing_page_url | https://doi.org/10.1111/iju.14882 |
| locations[1].id | pmid:35362143 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | International journal of urology : official journal of the Japanese Urological Association |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/35362143 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:9111834 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Int J Urol |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/9111834 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5047741139 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Kyo Togashi |
| authorships[0].countries | JP |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[0].affiliations[0].raw_affiliation_string | Department of Urology, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[0].institutions[0].id | https://openalex.org/I146516829 |
| authorships[0].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[0].institutions[0].country_code | JP |
| authorships[0].institutions[0].display_name | Hirosaki University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Kyo Togashi |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Department of Urology, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[1].author.id | https://openalex.org/A5011348912 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-0026-4079 |
| authorships[1].author.display_name | Shingo Hatakeyama |
| authorships[1].countries | JP |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[1].affiliations[0].raw_affiliation_string | Department of Advanced Blood Purification Therapy, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[1].institutions[0].id | https://openalex.org/I146516829 |
| authorships[1].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[1].institutions[0].country_code | JP |
| authorships[1].institutions[0].display_name | Hirosaki University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Shingo Hatakeyama |
| authorships[1].is_corresponding | True |
| authorships[1].raw_affiliation_strings | Department of Advanced Blood Purification Therapy, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[2].author.id | https://openalex.org/A5080302805 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-1098-407X |
| authorships[2].author.display_name | Tohru Yoneyama |
| authorships[2].countries | JP |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[2].affiliations[0].raw_affiliation_string | Department of Glycotechnology, Center for Advanced Medical Research, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[2].institutions[0].id | https://openalex.org/I146516829 |
| authorships[2].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[2].institutions[0].country_code | JP |
| authorships[2].institutions[0].display_name | Hirosaki University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Tohru Yoneyama |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Department of Glycotechnology, Center for Advanced Medical Research, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[3].author.id | https://openalex.org/A5054763232 |
| authorships[3].author.orcid | |
| authorships[3].author.display_name | Tomoko Hamaya |
| authorships[3].countries | JP |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Urology, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[3].institutions[0].id | https://openalex.org/I146516829 |
| authorships[3].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[3].institutions[0].country_code | JP |
| authorships[3].institutions[0].display_name | Hirosaki University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Tomoko Hamaya |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Urology, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[4].author.id | https://openalex.org/A5044499778 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-2572-3590 |
| authorships[4].author.display_name | Takuma Narita |
| authorships[4].countries | JP |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[4].affiliations[0].raw_affiliation_string | Department of Urology, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[4].institutions[0].id | https://openalex.org/I146516829 |
| authorships[4].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[4].institutions[0].country_code | JP |
| authorships[4].institutions[0].display_name | Hirosaki University |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Takuma Narita |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Department of Urology, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[5].author.id | https://openalex.org/A5034118045 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-8284-9582 |
| authorships[5].author.display_name | Naoki Fujita |
| authorships[5].countries | JP |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[5].affiliations[0].raw_affiliation_string | Department of Urology, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[5].institutions[0].id | https://openalex.org/I146516829 |
| authorships[5].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[5].institutions[0].country_code | JP |
| authorships[5].institutions[0].display_name | Hirosaki University |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Naoki Fujita |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Department of Urology, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[6].author.id | https://openalex.org/A5000448586 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-0304-4650 |
| authorships[6].author.display_name | Hiromichi Iwamura |
| authorships[6].countries | JP |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[6].affiliations[0].raw_affiliation_string | Department of Urology, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[6].institutions[0].id | https://openalex.org/I146516829 |
| authorships[6].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[6].institutions[0].country_code | JP |
| authorships[6].institutions[0].display_name | Hirosaki University |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Hiromichi Iwamura |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Department of Urology, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[7].author.id | https://openalex.org/A5026803124 |
| authorships[7].author.orcid | https://orcid.org/0000-0002-3750-3811 |
| authorships[7].author.display_name | Teppei Okamoto |
| authorships[7].countries | JP |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[7].affiliations[0].raw_affiliation_string | Department of Urology, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[7].institutions[0].id | https://openalex.org/I146516829 |
| authorships[7].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[7].institutions[0].country_code | JP |
| authorships[7].institutions[0].display_name | Hirosaki University |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | Teppei Okamoto |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Department of Urology, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[8].author.id | https://openalex.org/A5013782799 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-4557-0619 |
| authorships[8].author.display_name | Hayato Yamamoto |
| authorships[8].countries | JP |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[8].affiliations[0].raw_affiliation_string | Department of Urology, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[8].institutions[0].id | https://openalex.org/I146516829 |
| authorships[8].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[8].institutions[0].type | education |
| authorships[8].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[8].institutions[0].country_code | JP |
| authorships[8].institutions[0].display_name | Hirosaki University |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Hayato Yamamoto |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Department of Urology, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[9].author.id | https://openalex.org/A5066536967 |
| authorships[9].author.orcid | https://orcid.org/0000-0003-1061-827X |
| authorships[9].author.display_name | Takahiro Yoneyama |
| authorships[9].countries | JP |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[9].affiliations[0].raw_affiliation_string | Department of Advanced Transplant and Regenerative Medicine, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[9].institutions[0].id | https://openalex.org/I146516829 |
| authorships[9].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[9].institutions[0].type | education |
| authorships[9].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[9].institutions[0].country_code | JP |
| authorships[9].institutions[0].display_name | Hirosaki University |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Takahiro Yoneyama |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Department of Advanced Transplant and Regenerative Medicine, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[10].author.id | https://openalex.org/A5016000795 |
| authorships[10].author.orcid | https://orcid.org/0000-0003-0967-6835 |
| authorships[10].author.display_name | Yasuhiro Hashimoto |
| authorships[10].countries | JP |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[10].affiliations[0].raw_affiliation_string | Department of Urology, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[10].institutions[0].id | https://openalex.org/I146516829 |
| authorships[10].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[10].institutions[0].type | education |
| authorships[10].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[10].institutions[0].country_code | JP |
| authorships[10].institutions[0].display_name | Hirosaki University |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Yasuhiro Hashimoto |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Department of Urology, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[11].author.id | https://openalex.org/A5076273759 |
| authorships[11].author.orcid | https://orcid.org/0000-0003-1550-8379 |
| authorships[11].author.display_name | Chikara Οhyama |
| authorships[11].countries | JP |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I146516829 |
| authorships[11].affiliations[0].raw_affiliation_string | Department of Urology, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[11].affiliations[1].institution_ids | https://openalex.org/I146516829 |
| authorships[11].affiliations[1].raw_affiliation_string | Department of Advanced Blood Purification Therapy, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[11].affiliations[2].institution_ids | https://openalex.org/I146516829 |
| authorships[11].affiliations[2].raw_affiliation_string | Department of Glycotechnology, Center for Advanced Medical Research, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| authorships[11].institutions[0].id | https://openalex.org/I146516829 |
| authorships[11].institutions[0].ror | https://ror.org/02syg0q74 |
| authorships[11].institutions[0].type | education |
| authorships[11].institutions[0].lineage | https://openalex.org/I146516829 |
| authorships[11].institutions[0].country_code | JP |
| authorships[11].institutions[0].display_name | Hirosaki University |
| authorships[11].author_position | last |
| authorships[11].raw_author_name | Chikara Ohyama |
| authorships[11].is_corresponding | False |
| authorships[11].raw_affiliation_strings | Department of Advanced Blood Purification Therapy, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan, Department of Glycotechnology, Center for Advanced Medical Research, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan, Department of Urology, Hirosaki University School of Medicine, Hirosaki, Aomori, Japan |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.ncbi.nlm.nih.gov/pmc/articles/9111834 |
| open_access.oa_status | green |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Effect of active anticancer therapy on serologic response to SARS‐CoV‐2 BNT162b2 vaccine in patients with urothelial and renal cell carcinoma |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11296 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9980999827384949 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | COVID-19 and healthcare impacts |
| related_works | https://openalex.org/W2513932276, https://openalex.org/W2009347848, https://openalex.org/W2052465442, https://openalex.org/W4200167841, https://openalex.org/W2381991529, https://openalex.org/W2046566483, https://openalex.org/W2118520178, https://openalex.org/W2038865602, https://openalex.org/W4313375248, https://openalex.org/W4366772733 |
| cited_by_count | 5 |
| counts_by_year[0].year | 2023 |
| counts_by_year[0].cited_by_count | 2 |
| counts_by_year[1].year | 2022 |
| counts_by_year[1].cited_by_count | 3 |
| locations_count | 3 |
| best_oa_location.id | pmh:oai:pubmedcentral.nih.gov:9111834 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S2764455111 |
| best_oa_location.source.issn | |
| best_oa_location.source.type | repository |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | |
| best_oa_location.source.is_core | False |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | PubMed Central |
| best_oa_location.source.host_organization | https://openalex.org/I1299303238 |
| best_oa_location.source.host_organization_name | National Institutes of Health |
| best_oa_location.source.host_organization_lineage | https://openalex.org/I1299303238 |
| best_oa_location.license | |
| best_oa_location.pdf_url | |
| best_oa_location.version | submittedVersion |
| best_oa_location.raw_type | Text |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | False |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | Int J Urol |
| best_oa_location.landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/9111834 |
| primary_location.id | doi:10.1111/iju.14882 |
| primary_location.is_oa | False |
| primary_location.source.id | https://openalex.org/S134892809 |
| primary_location.source.issn | 0919-8172, 1442-2042 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0919-8172 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | International Journal of Urology |
| primary_location.source.host_organization | https://openalex.org/P4310320595 |
| primary_location.source.host_organization_name | Wiley |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320595 |
| primary_location.source.host_organization_lineage_names | Wiley |
| primary_location.license | |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | International Journal of Urology |
| primary_location.landing_page_url | https://doi.org/10.1111/iju.14882 |
| publication_date | 2022-03-31 |
| publication_year | 2022 |
| referenced_works | https://openalex.org/W3112675846, https://openalex.org/W3172958999, https://openalex.org/W3200303519, https://openalex.org/W3182782630, https://openalex.org/W3164768289, https://openalex.org/W3204258336, https://openalex.org/W3113007489, https://openalex.org/W3169202067, https://openalex.org/W3159611165, https://openalex.org/W3200773128, https://openalex.org/W3182456480, https://openalex.org/W3198699950, https://openalex.org/W2911812451, https://openalex.org/W2792937256, https://openalex.org/W2913745075, https://openalex.org/W3084419359, https://openalex.org/W3183900543, https://openalex.org/W3173907399, https://openalex.org/W3214000413, https://openalex.org/W3158078097, https://openalex.org/W3119364446, https://openalex.org/W3172450091, https://openalex.org/W3157335169, https://openalex.org/W3166460483, https://openalex.org/W3181254567, https://openalex.org/W3170537423, https://openalex.org/W3183904285, https://openalex.org/W3047764989, https://openalex.org/W4210261447, https://openalex.org/W4226094308, https://openalex.org/W4220758594, https://openalex.org/W4210585357, https://openalex.org/W4226205356 |
| referenced_works_count | 33 |
| abstract_inverted_index.2 | 79, 176, 203, 277 |
| abstract_inverted_index.G | 69, 179, 206 |
| abstract_inverted_index.21 | 154 |
| abstract_inverted_index.28 | 46, 156 |
| abstract_inverted_index.37 | 149 |
| abstract_inverted_index.57 | 40, 151 |
| abstract_inverted_index.60 | 35 |
| abstract_inverted_index.85 | 147 |
| abstract_inverted_index.Of | 145 |
| abstract_inverted_index.To | 1 |
| abstract_inverted_index.We | 65, 89 |
| abstract_inverted_index.an | 252 |
| abstract_inverted_index.as | 86 |
| abstract_inverted_index.at | 61 |
| abstract_inverted_index.in | 13, 98, 111, 134, 279 |
| abstract_inverted_index.of | 57, 150, 155 |
| abstract_inverted_index.or | 217, 247 |
| abstract_inverted_index.to | 6, 256 |
| abstract_inverted_index.we | 29 |
| abstract_inverted_index.500 | 125 |
| abstract_inverted_index.96% | 133 |
| abstract_inverted_index.age | 231 |
| abstract_inverted_index.and | 18, 26, 45, 96, 104, 116, 124, 132, 139, 153, 166, 182, 194, 232, 237, 284 |
| abstract_inverted_index.for | 163, 220 |
| abstract_inverted_index.had | 53 |
| abstract_inverted_index.not | 185, 210, 264 |
| abstract_inverted_index.the | 3, 7, 58, 67, 73, 99, 112, 135, 146, 189, 257 |
| abstract_inverted_index.two | 55 |
| abstract_inverted_index.was | 84, 129, 184, 263 |
| abstract_inverted_index.who | 52 |
| abstract_inverted_index.2021 | 25 |
| abstract_inverted_index.431, | 123 |
| abstract_inverted_index.813, | 122 |
| abstract_inverted_index.90%, | 131 |
| abstract_inverted_index.June | 24 |
| abstract_inverted_index.acid | 11 |
| abstract_inverted_index.cell | 20, 50, 106, 118, 141, 168, 196, 249, 286 |
| abstract_inverted_index.from | 34 |
| abstract_inverted_index.that | 229 |
| abstract_inverted_index.were | 121, 158, 209, 235 |
| abstract_inverted_index.with | 15, 42, 48, 93, 101, 191, 213, 240, 244, 267, 271, 281 |
| abstract_inverted_index.(65%) | 152 |
| abstract_inverted_index.(75%) | 157 |
| abstract_inverted_index.100%, | 130 |
| abstract_inverted_index.2021, | 28 |
| abstract_inverted_index.U/mL, | 126 |
| abstract_inverted_index.U/mL. | 88 |
| abstract_inverted_index.acute | 75, 172, 199, 273 |
| abstract_inverted_index.blood | 32 |
| abstract_inverted_index.doses | 56 |
| abstract_inverted_index.older | 230 |
| abstract_inverted_index.renal | 19, 49, 105, 117, 140, 167, 195, 248, 285 |
| abstract_inverted_index.spike | 80, 177, 204 |
| abstract_inverted_index.≥15 | 87 |
| abstract_inverted_index.Active | 260 |
| abstract_inverted_index.active | 214 |
| abstract_inverted_index.groups | 120 |
| abstract_inverted_index.severe | 74, 272 |
| abstract_inverted_index.titers | 71, 95, 110, 181, 208 |
| abstract_inverted_index.Between | 23 |
| abstract_inverted_index.Methods | 22 |
| abstract_inverted_index.Results | 108 |
| abstract_inverted_index.adverse | 222 |
| abstract_inverted_index.against | 72 |
| abstract_inverted_index.between | 188 |
| abstract_inverted_index.defined | 85 |
| abstract_inverted_index.disease | 234 |
| abstract_inverted_index.domain. | 82 |
| abstract_inverted_index.events. | 223 |
| abstract_inverted_index.factors | 91 |
| abstract_inverted_index.group), | 39 |
| abstract_inverted_index.groups, | 143 |
| abstract_inverted_index.healthy | 36 |
| abstract_inverted_index.samples | 33 |
| abstract_inverted_index.steroid | 218 |
| abstract_inverted_index.therapy | 216, 262 |
| abstract_inverted_index.vaccine | 12, 60 |
| abstract_inverted_index.(control | 38 |
| abstract_inverted_index.Antibody | 109 |
| abstract_inverted_index.BNT162b2 | 8, 59, 258, 278 |
| abstract_inverted_index.Hirosaki | 62 |
| abstract_inverted_index.November | 27 |
| abstract_inverted_index.Patients | 243 |
| abstract_inverted_index.actively | 159 |
| abstract_inverted_index.adequate | 253 |
| abstract_inverted_index.analysis | 227 |
| abstract_inverted_index.antibody | 70, 94, 180, 207, 254 |
| abstract_inverted_index.control, | 113, 136 |
| abstract_inverted_index.controls | 37 |
| abstract_inverted_index.evaluate | 2 |
| abstract_inverted_index.logistic | 225 |
| abstract_inverted_index.patients | 14, 41, 47, 100, 190, 280 |
| abstract_inverted_index.received | 54 |
| abstract_inverted_index.response | 5, 255 |
| abstract_inverted_index.revealed | 228 |
| abstract_inverted_index.syndrome | 77, 174, 201, 275 |
| abstract_inverted_index.vaccine. | 259 |
| abstract_inverted_index.Hospital. | 64 |
| abstract_inverted_index.carcinoma | 17, 51, 103, 119, 142, 165, 193, 246, 250, 283 |
| abstract_inverted_index.different | 187 |
| abstract_inverted_index.evaluated | 31 |
| abstract_inverted_index.exhibited | 251 |
| abstract_inverted_index.following | 269 |
| abstract_inverted_index.messenger | 9 |
| abstract_inverted_index.patients, | 148 |
| abstract_inverted_index.serologic | 4 |
| abstract_inverted_index.treatment | 162, 219 |
| abstract_inverted_index.Objectives | 0 |
| abstract_inverted_index.University | 63 |
| abstract_inverted_index.anticancer | 161, 215, 261 |
| abstract_inverted_index.associated | 92, 212, 239, 266 |
| abstract_inverted_index.carcinoma, | 44, 115, 138, 169 |
| abstract_inverted_index.carcinoma. | 21, 107, 197, 287 |
| abstract_inverted_index.determined | 66 |
| abstract_inverted_index.metastatic | 233 |
| abstract_inverted_index.negatively | 238 |
| abstract_inverted_index.regression | 226 |
| abstract_inverted_index.undergoing | 160 |
| abstract_inverted_index.urothelial | 16, 43, 102, 114, 137, 164, 192, 245, 282 |
| abstract_inverted_index.Conclusions | 242 |
| abstract_inverted_index.Univariable | 224 |
| abstract_inverted_index.coronavirus | 78, 175, 202, 276 |
| abstract_inverted_index.investigate | 90 |
| abstract_inverted_index.respiratory | 76, 173, 200, 274 |
| abstract_inverted_index.ribonucleic | 10 |
| abstract_inverted_index.vaccination | 270 |
| abstract_inverted_index.Anti‐severe | 171, 198 |
| abstract_inverted_index.respectively. | 127, 144, 170 |
| abstract_inverted_index.significantly | 186, 211, 236, 265 |
| abstract_inverted_index.Seropositivity | 83, 128 |
| abstract_inverted_index.immunoglobulin | 68, 178, 205 |
| abstract_inverted_index.seropositivity | 97, 183, 268 |
| abstract_inverted_index.retrospectively | 30 |
| abstract_inverted_index.seropositivity. | 241 |
| abstract_inverted_index.immune‐related | 221 |
| abstract_inverted_index.receptor‐binding | 81 |
| cited_by_percentile_year.max | 97 |
| cited_by_percentile_year.min | 94 |
| corresponding_author_ids | https://openalex.org/A5011348912 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 12 |
| corresponding_institution_ids | https://openalex.org/I146516829 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/3 |
| sustainable_development_goals[0].score | 0.8700000047683716 |
| sustainable_development_goals[0].display_name | Good health and well-being |
| citation_normalized_percentile.value | 0.66845574 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |